Non‑alcoholic fatty liver disease and hematologic manifestations (Review)

Pădureanu,Vlad; Dop,Dalia; Drăgoescu,Alice Nicoleta; Pădureanu,Rodica; Mușetescu,Anca Emanuela; Nedelcu,Laurențiu

doi:10.3892/etm.2021.10790

Non‑alcoholic fatty liver disease and hematologic manifestations (Review)

Authors:
- Vlad Pădureanu
- Dalia Dop
- Alice Nicoleta Drăgoescu
- Rodica Pădureanu
- Anca Emanuela Mușetescu
- Laurențiu Nedelcu
View Affiliations

Affiliations: Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Anesthesiology and Intensive Care, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Internal Medicine, Emergency Clinical County Hospital of Craiova, 200642 Craiova, Romania, Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Internal Medicine, Faculty of Medicine, Transylvania University Brasov, 500019 Brașov, Romania
Published online on: September 23, 2021 https://doi.org/10.3892/etm.2021.10790
Article Number: 1355
Copyright: © Pădureanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) is a multisystem disease, and it is associated with numerous extra‑hepatic manifestations or additional co‑occurring diseases. The aim of the present review was the identification and management of the hematologic manifestations of NAFLD. One of the triggers is considered to be iron abnormalities. Increased ferritin levels, hepatic iron deposits and iron overload are associated with NAFLD. The iron overload degree and severity are associated with the level of liver fibrosis and with the risk for hepatocellular carcinoma. Excess iron deposits refers to the dysmetabolic iron overload syndrome (DIOS) and it is characterized by steatosis associated with moderate tissue iron deposition and increased levels of serum ferritin, while the serum transferrin saturation was normal. Further prospective studies are necessary to determine whether NAFLD has an independent risk for hematologic symptoms, besides the known risk factors. Future studies are also needed in order to assess the increasing impact of NAFLD on the micro‑ and macro‑vascular complications of this systemic disease.

View Figures

View References

1	Tariq R, Axley P and Singal AK: Extra-hepatic manifestations of nonalcoholic fatty liver disease: A review. J Clin Exp Hepatol. 10:81–87. 2020.PubMed/NCBI View Article : Google Scholar
2	Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, Raponi M and Dhawan A: Nonalcoholic fatty liver disease: A challenge for pediatricians. JAMA Pediatr. 169:170–176. 2015.PubMed/NCBI View Article : Google Scholar
3	Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL and Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 140:124–131. 2011.PubMed/NCBI View Article : Google Scholar
4	Wijarnpreecha K, Aby ES, Ahmed A and Kim D: Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol. 27:221–235. 2021.PubMed/NCBI View Article : Google Scholar
5	Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016.PubMed/NCBI View Article : Google Scholar
6	Vernon G, Baranova A and Younossi ZM: Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011.PubMed/NCBI View Article : Google Scholar
7	Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419. 1999.PubMed/NCBI View Article : Google Scholar
8	Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E and Gastaldelli A: Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 5:1544–1560. 2013.PubMed/NCBI View Article : Google Scholar
9	Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, Cohen DE and Loomba R: From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 73:1194–1198. 2021.PubMed/NCBI View Article : Google Scholar
10	Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology. 67:328–357. 2018.PubMed/NCBI View Article : Google Scholar
11	Byrne CD and Targher G: NAFLD: A multisystem disease. J Hepatol. 62 (Suppl 1):S47–S64. 2015.PubMed/NCBI View Article : Google Scholar
12	Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S and Hultcrantz R: Fibrosis stage is the strongest predictor for disease specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 61:1547–1554. 2015.PubMed/NCBI View Article : Google Scholar
13	Rinella ME: Nonalcoholic fatty liver disease: A systematic review. JAMA. 313:2263–2273. 2015.PubMed/NCBI View Article : Google Scholar
14	Li AA, Ahmed A and Kim D: Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 14:168–178. 2020.PubMed/NCBI View Article : Google Scholar
15	Sebastiani G and Alberti A: Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 12:3682–3694. 2006.PubMed/NCBI View Article : Google Scholar
16	West J and Card TR: Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 139:1230–1237. 2010.PubMed/NCBI View Article : Google Scholar
17	Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T and Younossi ZM: Long-term follow-up of patients with non-alcoholic fatty liver. Clin Gastroenterol Hepatol. 7:234–238. 2009.PubMed/NCBI View Article : Google Scholar
18	Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A and Angulo P: The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 129:113–121. 2005.PubMed/NCBI View Article : Google Scholar
19	VanWagner LB and Rinella ME: Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep. 15:75–85. 2016.PubMed/NCBI View Article : Google Scholar
20	Kim D, Kim WR, Kim HJ and Therneau TM: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 57:1357–1365. 2013.PubMed/NCBI View Article : Google Scholar
21	Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ and Nelson JE: NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 55:77–85. 2012.PubMed/NCBI View Article : Google Scholar
22	Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G and Rizzetto M: Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 39:179–187. 2004.PubMed/NCBI View Article : Google Scholar
23	Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A and Vecchione R: Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 50:351–357. 2009.PubMed/NCBI View Article : Google Scholar
24	Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G and Fargion S: HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterology. 138:905–912. 2010.PubMed/NCBI View Article : Google Scholar
25	Duseja A, Das R, Nanda M, Das A, Garewal G and Chawla Y: Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol. 11:393–395. 2005.PubMed/NCBI View Article : Google Scholar
26	Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, et al: The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 61:1555–1564. 2015.PubMed/NCBI View Article : Google Scholar
27	Agbim U, Jiang Y, Kedia SK, Singal AK, Ahmed A, Bhamidimarri KR, Bernstein DE, Harrison SA, Younossi ZM and Satapathy SK: Impact of nonmalignant portal vein thrombosis in transplant recipients with nonalcoholic steatohepatitis. Liver Transpl. 25:68–78. 2019.PubMed/NCBI View Article : Google Scholar
28	Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V and Deugnier Y: Insulin resistance-associated hepatic iron overload. Gastroenterology. 117:1155–1163. 1999.PubMed/NCBI View Article : Google Scholar
29	Mihailovici AR, Padureanu V, Albu CV, Dinescu VC, Pirlog MC, Dinescu SN, Malin RD and Calborean V: Myocardial Noncompaction. Rev Chim (Bucharest). 69:2209–2212. 2018.
30	Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P and Deugnier Y: A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 349:95–97. 1997.PubMed/NCBI View Article : Google Scholar
31	ForȚofoiu MC, Popescu DM, Pădureanu V, Dobrinescu AC, Dobrinescu AG, Mită A, Foarfă MC, Bălă VS, Muşetescu AE, Ionovici N and ForŢofoiu M: Difficulty in positive diagnosis of ascites and in differential diagnosis of a pulmonary tumor. Rom J Morphol Embryol. 58:1057–1064. 2017.PubMed/NCBI
32	Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, Liaquat H, Mezzabotta L, Lee E and Bugianesi E: Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 12:1163–1169.e1. 2014.PubMed/NCBI View Article : Google Scholar
33	Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A and Kowdley KV: Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 53:448–457. 2011.PubMed/NCBI View Article : Google Scholar
34	Forţofoiu M, Forţofoiu MC, Comănescu V, Dobrinescu AC, Pădureanu V, Vere CC, Streba CT and Ciurea PL: Hepatocellular carcinoma and metabolic diseases - histological perspectives from a series of 14 cases. Rom J Morphol Embryol. 56:1461–1465. 2015.PubMed/NCBI
35	Găman AE, Ungureanu AM, Turculeanu A, Gheonea DI, Drocaş AI, Mitroi G, DobriȚoiu M, Comănescu MV, Stănculescu AD, Cioboată R, et al: The impact of liver steatosis on early and sustained treatment response in chronic hepatitis C patients. Rom J Morphol Embryol. 58:107–113. 2017.PubMed/NCBI
36	Furtunescu F, Minca DG, Vasile A and Domnariu C: Alcohol consumption impact on premature mortality in Romania. Rom J Leg Med. 17:296–302. 2009.